UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/718,155	11/20/2003	Christopher J. Moran	3433-483	9003
Woodard, Emhardt, Moriarty, McNett & Henry LLP Bank One Center/Tower			EXAMINER	
			BUI, VY Q	
Suite 3700 111 Monument Circle		ART UNIT	PAPER NUMBER	
Indianapolis, IN 46204-5137			3773	
			MAIL DATE	DELIVERY MODE
			07/10/2008	PAPER

# Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
	10/718,155	MORAN ET AL.
Office Action Summary	Examiner	Art Unit
	Vy Q. Bui	3773
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the c	orrespondence address
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.1. after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period v  - Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tin will apply and will expire SIX (6) MONTHS from , cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).
Status		
Responsive to communication(s) filed on <u>24 M</u> This action is <b>FINAL</b> . 2b) ☐ This     Since this application is in condition for alloware closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro	
Disposition of Claims		
4)  Claim(s) 27-44 is/are pending in the application 4a) Of the above claim(s) 28,30 and 34-36 is/an 5)  Claim(s) is/are allowed.  6)  Claim(s) 27,29,31-33 and 37-44 is/are rejected 7)  Claim(s) is/are objected to.  8)  Claim(s) are subject to restriction and/o	re withdrawn from consideration.	
Application Papers		
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomposed and all accomposed and all accomposed and accomposed accomposed and accomposed	epted or b) objected to by the Idrawing(s) be held in abeyance. See iion is required if the drawing(s) is obj	e 37 CFR 1.85(a). lected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage
Attachment(s)	4) 🗖 Indonésia - 0	(PTO 442)
<ol> <li>Notice of References Cited (PTO-892)</li> <li>Notice of Draftsperson's Patent Drawing Review (PTO-948)</li> <li>Information Disclosure Statement(s) (PTO/SB/08)</li> <li>Paper No(s)/Mail Date</li> </ol>	4)  Interview Summary Paper No(s)/Mail Da 5)  Notice of Informal P 6)  Other:	nte

#### **DETAILED ACTION**

#### Election/Restrictions

Claims 28, 30, 34-36 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made **without** traverse in the reply filed on 3/23/2007 and is now made final.

## Claim Rejections - 35 USC § 102

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

Claims 27, 29, 31-33, 38, 40, 42-44 are rejected under 35 U.S.C. 102(e) as being anticipated by Babbs et al.- WO98/25544, which is the same as US Pat. 6,475,232.

Babbs-'232 discloses an occluding device including a stent and a cover/graft made of a submucosa such as a porcine submucosa deployed in a blood vessel. Notice that the stent and the cover physically occlude the lumen of the blood vessel to keep the lumen open from a stenosis. Babbs-'232 substantially discloses comminuted submucosa (col. 5, lines 27-39) or sheet like submucosa or injectable/fluidized submucosa (col. 3, lines 42-45).

Notice that Babbs-'232 stent-graft causes **a full occlusion** and a **full blockage** of a vascular vessel because the stent-graft device covers the whole **360-degree circumference** of the vascular vessel. Moreover, Babbs-'232 stent-graft device is at least capable of fully blocking an aneurysm located in a side wall of a vascular vessel, such as an aneurysm shown in F. 7 of the present invention. The term "full" is broad and a "full occlusion" can be reasonably interpreted as an occlusion covering 360 degrees around a blood vessel inner surface and still allow a blood flow in the center portion of the blood vessel's lumen.

#### Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 37, 39 and 41 are rejected under 35 U.S.C. 103(a) as being unpatentable over Babbs et al.- WO98/25544, which is the same as US Pat. 6,475,232 in view of Li-5,512,291.

Babbs-'232 discloses substantially the claimed invention, except for a pharmacologic agent, or an antibiotic, or a radiopaque agent. However, Li-'291 discloses radiopaque material BaSO<sub>4</sub> for easy visualization of the device (col. 13, lines 63-65; col. 5, lines 26-27) and an antibiotic for prevention of an infection (col. 5, lines 17-27). It would have been obvious to one of ordinary skill in the art to provide Babbs-'232 a radiopaque agent for easy visualization of the device or an antibiotic agent for treatment of an infection.

## Response to Arguments

Applicant's arguments filed 10/12/2007 have been fully considered but they are not persuasive.

As indicated in the above rejection, at least Babbs-'232 stent-graft is capable of causing a full blockage of a vascular vessel or an aneurysm at the wall of a vascular vessel. Babbs-'232 stent-graft is also considered as to cause a full occlusion because Babbs-'232 stent-graft fully occlude the whole 360 degrees of a blood vessel. The term "full" is broad and can be reasonably interpreted as indicated above and the claim language does not require Babbs-'232 stent-graft to occlude the "whole passage/lumen" of the blood vessel.

### Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Vy Q. Bui whose telephone number is 571-272-4692. The examiner can normally be reached on Monday-Tuesday and Thursday-Friday.

Application/Control Number: 10/718,155 Page 5

Art Unit: 3773

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jackie Ho can be reached on 571-272-4696. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Vy Q. Bui/

Primary Examiner, Art Unit 3773